GlassScriptPhysician profile
Christopher Botros Rizk
NPI 1134514979
$16,441.47
in general payments reported to CMS, 2019-2025
27 companies · $1,509 in 2025
The $1,509 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,127 · 2020: $1,475 · 2021: $1,698 · 2022: $1,787 · 2023: $5,451 · 2024: $3,395 · 2025: $1,509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,019 · Food and Beverage: $3,336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,019.45 |
| Food and Beverage | $3,335.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $8,023.37 | 2019-2025 | Skyrizi |
| Revance Therapeutics, INC. | $2,637.68 | 2024-2025 | Daxxify, Daxi |
| Galderma Laboratories, L.P. | $1,134.85 | 2019-2022 | |
| Merz North America, INC. | $960.98 | 2022-2023 | Xeomin |
| Leo Pharma INC. | $449.92 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $433.45 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $428.49 | 2019-2022 | |
| Genzyme Corporation | $255.22 | 2019-2022 | |
| Journey Medical Corporation | $250.00 | 2022 | |
| Allergan, INC. | $227.59 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $219.05 | 2019-2020 | |
| Encore Dermatology INC. | $210.24 | 2019 | |
| Lilly USA, LLC | $194.13 | 2020-2024 | Taltz, Olumiant |
| Solta Medical, A Division of Bausch Health US, LLC | $149.48 | 2024 | |
| Vyne Pharmaceuticals INC. | $145.62 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $137.92 | 2021-2022 | |
| Celgene Corporation | $131.42 | 2019 | |
| Amgen INC. | $121.48 | 2020-2023 | Otezla |
| Janssen Scientific Affairs, LLC | $109.61 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $43.84 | 2021 | |
| Pfizer INC. | $41.15 | 2021 | |
| Hill Dermaceuticals, INC. | $35.89 | 2020 | |
| Incyte Corporation | $34.48 | 2022-2023 | Opzelura |
| Helsinn Therapeutics (U.S.), INC. | $19.24 | 2021 | |
| Ucb, INC. | $15.87 | 2022 | |
| Dermira, INC. | $15.48 | 2020 | |
| Sun Pharmaceutical Industries INC. | $15.02 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Rizk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.